You have 9 free searches left this month | for more free features.

Azacytidine

Showing 1 - 25 of 248

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Squamous Cell Carcinoma of Head and Neck Trial (Combination 5-azacytidine and nivolumab, 5-azacytidine, Nivolumab)

Not yet recruiting
  • Squamous Cell Carcinoma of Head and Neck
  • Combination 5-azacytidine and nivolumab
  • +2 more
  • (no location specified)
Dec 7, 2022

Recurrent Ependymoma Trial in Houston (5-Azacytidine (5-AZA) group 1, 5-Azacytidine (5-AZA) group 2, 5-Azacytidine (5-AZA) group

Recruiting
  • Recurrent Ependymoma
  • 5-Azacytidine (5-AZA) group 1
  • +2 more
  • Houston, Texas
    The University of Texas Health Science Center at Houston
Aug 17, 2022

Leukemia Trial in Houston (Brentuximab Vedotin, 5-Azacytidine)

Terminated
  • Leukemia
  • Houston, Texas
    University of Texas MD Anderson Cancer Center
Sep 7, 2022

Myelodysplastic/Myeloproliferative Tumor, Unclassifiable, Myelofibrosis Transformation in Essential Thrombocythemia,

Recruiting
  • Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable
  • +3 more
  • Houston, Texas
    M D Anderson Cancer Center
Aug 18, 2022

Myelodysplastic Syndrome Trial in Japan (SyB C-1101 and Azacytidine)

Withdrawn
  • Myelodysplastic Syndrome
  • SyB C-1101 and Azacytidine
  • Nagoya, Aichi, Japan
  • +3 more
Nov 14, 2022

Acute Myeloid Leukaemia; MDS;Chronic Myelomonocytic Leukemia Trial in Shenzhen (Azacytidine, HAG Regimen, Azacytidine)

Recruiting
  • Acute Myeloid Leukaemia; Myelodysplastic Syndromes;Chronic Myelomonocytic Leukemia
  • Azacytidine, HAG Regimen
  • Azacytidine
  • Shenzhen, Guangdong, China
    Shenzhen Second People's Hospital
Mar 14, 2022

Allogeneic Hematopoietic Stem Cell Transplantation, Acute Lymphoblastic Leukemia Trial in Suzhou (VEN+AZA+Modified BUCY)

Recruiting
  • Allogeneic Hematopoietic Stem Cell Transplantation
  • Acute Lymphoblastic Leukemia
  • VEN+AZA+Modified BUCY
  • Suzhou, Jiangsu, China
    The First Affiliated Hospital of Soochow University
Apr 10, 2023

Acute Myeloid Leukemia Trial in Suzhou (Venetoclax Oral Tablet, Daunorubicin)

Recruiting
  • Acute Myeloid Leukemia
  • Suzhou, Jiangsu, China
  • +1 more
Jul 3, 2023

Chronic Myelomonocytic Leukemia-0, Chronic Myelomonocytic Leukemia-1, Chronic Myelomonocytic Leukemia-2 Trial in Houston

Active, not recruiting
  • Chronic Myelomonocytic Leukemia-0
  • +5 more
  • Houston, Texas
    M D Anderson Cancer Center
Jan 18, 2023

Allogeneic Hematopoietic Stem Cell Transplantation, Acute Myeloid Leukemia, Myelodysplastic Syndrome Trial in Suzhou

Recruiting
  • Allogeneic Hematopoietic Stem Cell Transplantation
  • +2 more
  • VEN+AZA+Modified BUCY
  • Suzhou, Jiangsu, China
    The First Affiliated Hospital of Soochow University
Apr 10, 2023

Acute Myeloid Leukemia in Remission, FLT3 Gene Mutation, Hematologic and Lymphocytic Disorder Trial in Houston (Azacitidine,

Recruiting
  • Acute Myeloid Leukemia in Remission
  • +5 more
  • Houston, Texas
    M D Anderson Cancer Center
Dec 13, 2022

Acute Bilineal Leukemia, Acute Biphenotypic Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome

Recruiting
  • Acute Bilineal Leukemia
  • +8 more
  • Houston, Texas
    M D Anderson Cancer Center
Jan 24, 2023

Acute Myeloid Leukemia Trial in Lanzhou (Venetoclax, Azacitidine, Cladribine)

Recruiting
  • Acute Myeloid Leukemia
  • Lanzhou, Gansu, China
    Long Zhao
Apr 24, 2022

Acute Myeloid Leukemia Trial in Los Angeles, San Francisco (Azacitidine, Tagraxofusp-erzs)

Not yet recruiting
  • Acute Myeloid Leukemia
  • Los Angeles, California
  • +1 more
Jan 31, 2023

Secondary Myelodysplastic Syndrome, Therapy-Related Myelodysplastic Syndrome Trial in Columbus (Azacitidine, Quality-of-Life

Recruiting
  • Secondary Myelodysplastic Syndrome
  • Therapy-Related Myelodysplastic Syndrome
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Dec 1, 2022

AML, Childhood Trial in United States (Nivolumab, 5-azacytidine)

Active, not recruiting
  • AML, Childhood
  • Los Angeles, California
  • +11 more
Oct 10, 2022

Acute Myeloid Leukemia Trial in Houston (Azacitidine, Venetoclax, NK Cells)

Not yet recruiting
  • Acute Myeloid Leukemia
  • Houston, Texas
    M.D. Anderson Cancer Center
Apr 17, 2023

High Risk Myelodysplastic Syndrome, IPSS Risk Category Intermediate-1, Myelodysplastic Syndrome Trial in Houston (Azacitidine,

Active, not recruiting
  • High Risk Myelodysplastic Syndrome
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Aug 11, 2022

Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndrome, Myelodysplastic Syndrome Trial in Scottsdale, Cleveland,

Completed
  • Chronic Myelomonocytic Leukemia
  • +3 more
  • Scottsdale, Arizona
  • +3 more
Jan 12, 2023

PTCL Trial in Long Beach, New Haven, Charlottesville (Azacytidine, Romidepsin, Belinostat)

Recruiting
  • PTCL
  • Azacytidine
  • +4 more
  • Long Beach, California
  • +2 more
Mar 1, 2022

Acute Myeloid Leukemia Trial in Chicago (Azacitidine, Biospecimen Collection, Bone Marrow Aspirate)

Not yet recruiting
  • Acute Myeloid Leukemia
  • Chicago, Illinois
    Northwestern University
Feb 16, 2023

Acute Myeloid Leukemia Trial in Sacramento (Azacitidine, Uproleselan, Venetoclax)

Recruiting
  • Acute Myeloid Leukemia
  • Sacramento, California
    University of California Davis Comprehensive Cancer Center
Aug 12, 2022

Hodgkin's Lymphoma Trial in Houston (Azacytidine, Pembrolizumab)

Recruiting
  • Hodgkin's Lymphoma
  • Houston, Texas
    MD Anderson Cancer Center
Oct 5, 2022

Acute Myeloid Leukemia, Myelodysplastic Syndrome Trial in Duarte (procedure, drug, biological, other)

Not yet recruiting
  • Acute Myeloid Leukemia
  • Myelodysplastic Syndrome
  • Allogeneic Hematopoietic Stem Cell Transplantation
  • +8 more
  • Duarte, California
    City of Hope Medical Center
Apr 10, 2023

MDS, MDS/MPN Crossover Syndromes Trial in Cleveland (5-azacytidine, Decitabine)

Recruiting
  • Myelodysplastic Syndromes
  • MDS/MPN Crossover Syndromes
  • Cleveland, Ohio
    Cleveland Medical Center, University Hospitals Seidman Cancer Ce
Aug 10, 2022